| gap-pubmed-20260410- | Does drebrin A reduction causally mediate NMDA receptor redistribution defects i | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What molecular mechanisms link presenilin loss to drebrin A reduction at synapse | open | 0.80 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What determines tissue-specific Foxo3a activation by FJT in oligodendrocytes ver | open | 0.73 | 0.00 | 2026-04-10 | 0 | | oligodendrocyte-biology |
| gap-pubmed-20260410- | How does cerebral MCAO lead to spinal cord remyelination deficits that FJT can r | open | 0.80 | 0.00 | 2026-04-10 | 0 | | stroke-recovery |
| gap-pubmed-20260410- | What is the relative contribution of ZBTB7C's effects on neuronal apoptosis vers | open | 0.79 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | How do ANGPT1 and ZBTB7C mechanistically regulate infarct size in ischemic strok | open | 0.80 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | Which gut microbiome interventions provide optimal therapeutic benefit for diffe | resolved | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms linking gut dysbiosis to MS neurodege | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What drives the spatial restriction of stressed oligodendrocytes and reactive gl | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do phagocytosing microglia/macrophages import and process ingested myelin tr | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms drive selective vulnerability of CUX2+ upper cortical neurons to | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does TDP-43 regulation of HERV-K expression integrate with known TDP-43 path | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why is HERV-K activated only in a subpopulation of ALS patients and what determi | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link HERV-K env protein expression to neurite retracti | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Which compartment-specific 1C metabolism targets (nuclear, cytoplasmic, mitochon | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do genetic polymorphisms in 1C metabolism genes specifically affect neurodeg | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific mechanisms by which 1C metabolism dysfunction contributes | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does HTT selectively recruit different mitophagy receptors to damaged versus | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific molecular mechanisms does polyQ expansion use to disrupt HTT-media | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do extensive matrix remodeling changes coordinate with adhesion signaling to | open | 0.76 | 0.00 | 2026-04-10 | 0 | | cancer-biology |
| gap-pubmed-20260410- | What molecular mechanisms link perlecan/HSPG2 upregulation to radioresistance ac | open | 0.80 | 0.00 | 2026-04-10 | 0 | | cancer-biology |
| gap-pubmed-20260410- | What determines the optimal balance between ROS scavenging and MMP consumption f | open | 0.81 | 0.00 | 2026-04-10 | 0 | | bioengineering |
| gap-pubmed-20260410- | How does HSPG2-DAG1 ligand-receptor interaction mechanistically promote fibrobla | open | 0.79 | 0.00 | 2026-04-10 | 0 | | dermatology |
| gap-pubmed-20260410- | Why does PAQR4 overexpression cause adipocyte de-differentiation through ceramid | open | 0.77 | 0.00 | 2026-04-10 | 0 | | metabolism |
| gap-pubmed-20260410- | What are the physiological ligands or activators of the orphan receptor PAQR4? | open | 0.79 | 0.00 | 2026-04-10 | 0 | | metabolism |
| gap-pubmed-20260410- | How does PAQR4 mechanistically regulate ceramide synthase stability and activity | open | 0.84 | 0.00 | 2026-04-10 | 0 | | metabolism |
| gap-pubmed-20260410- | Why does mitochondrial oxidation increase despite reduced mitochondrial calcium | open | 0.82 | 0.00 | 2026-04-10 | 0 | | metabolism |
| gap-pubmed-20260410- | How does cytosolic Ca2+ activation of CAMKII mechanistically regulate multiple d | open | 0.80 | 0.00 | 2026-04-10 | 0 | | metabolism |
| gap-pubmed-20260410- | How do TIGAR, TKT, and CTPS1 expression changes mechanistically link to poor pro | open | 0.72 | 0.00 | 2026-04-10 | 0 | | cancer-biology |
| gap-pubmed-20260410- | What determines whether IDH2-mediated metabolic reprogramming confers cross-resi | open | 0.79 | 0.00 | 2026-04-10 | 0 | | cancer-biology |
| gap-pubmed-20260410- | How does IDH2 gain-of-function mechanistically stabilize HIF-1α through reductiv | open | 0.82 | 0.00 | 2026-04-10 | 0 | | cancer-biology |
| gap-pubmed-20260410- | Which specific pharmacogenes are regulated by miR-375 and how do they collective | open | 0.83 | 0.00 | 2026-04-10 | 0 | | hepatotoxicology |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which miR-375 orchestrates pharmac | open | 0.82 | 0.00 | 2026-04-10 | 0 | | pharmacogenomics |
| gap-pubmed-20260410- | How does accelerated phospholipid mobilization from PTECs specifically drive tri | open | 0.76 | 0.00 | 2026-04-10 | 0 | | metabolism |
| gap-pubmed-20260410- | What molecular mechanisms link PTEC-specific enhanced autophagy to systemic meta | open | 0.79 | 0.00 | 2026-04-10 | 0 | | metabolism |
| gap-pubmed-20260410- | Why does enhanced autophagy in PTECs fail to protect against acute ischemic kidn | open | 0.82 | 0.00 | 2026-04-10 | 0 | | nephrology |
| gap-pubmed-20260410- | How does attenuation of TUG cleavage promote obesity in physiological conditions | open | 0.82 | 0.00 | 2026-04-10 | 0 | | metabolism |
| gap-pubmed-20260410- | What determines the nuclear translocation specificity of the TUG C-terminal clea | open | 0.80 | 0.00 | 2026-04-10 | 0 | | metabolism |
| gap-pubmed-20260410- | How does the TUG cleavage pathway contribute to the thermic effect of food in hu | open | 0.79 | 0.00 | 2026-04-10 | 0 | | metabolism |
| gap-pubmed-20260410- | What is the functional role of NAPSA in COVID-19 pathogenesis and alveolar gas e | open | 0.79 | 0.00 | 2026-04-10 | 0 | | respiratory-physiology |
| gap-pubmed-20260410- | How does the 17q21.31 inversion polymorphism mechanistically contribute to sever | open | 0.80 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-pubmed-20260410- | How do E2F7/E2F8 atypical repressors mechanistically coordinate the unique G2/M | open | 0.76 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-pubmed-20260410- | What molecular mechanisms determine tissue-specific endocycle regulation in trop | open | 0.73 | 0.00 | 2026-04-10 | 0 | | developmental-biology |
| gap-pubmed-20260410- | How do canonical E2Fs promote mitosis while simultaneously augmenting endocycle | open | 0.79 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-pubmed-20260410- | What mechanisms drive the selective increase in complete/near-complete responses | open | 0.77 | 0.00 | 2026-04-10 | 0 | | cancer-biology |
| gap-pubmed-20260410- | Why does panobinostat improve progression-free survival but not overall response | open | 0.79 | 0.00 | 2026-04-10 | 0 | | cancer-biology |
| gap-pubmed-20260410- | What defines 'penicillin failure' and what mechanisms underlie treatment failure | open | 0.58 | 0.00 | 2026-04-10 | 0 | | infectious |
| gap-pubmed-20260410- | Why do cephalosporins achieve more reliable β-hemolytic streptococci eradication | open | 0.64 | 0.00 | 2026-04-10 | 0 | | infectious |
| gap-pubmed-20260410- | What are the precise mechanisms by which testosterone stimulates erythropoiesis? | open | 0.77 | 0.00 | 2026-04-10 | 0 | | hematology |
| gap-pubmed-20260410- | Does TRT-induced erythrocytosis actually increase venous thromboembolism risk in | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | endocrinology |